SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
As of 18 November 2026, for the company name SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. as recorded, the chemical-drug catalogue lists 43 active records with this name as holder; 18 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.
Drug filings
165 acceptance records as first applicant, grouped into 36 source drug names. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
SAL0140片 · No verified English name 15 records · Latest accepted 2026/11/10
Supplement · 7New drug · 8
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2600490 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2600489 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2600488 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2600487 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2600486 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2600485 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2501045 | New drug | 2025/09/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2501044 | New drug | 2025/09/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2501043 | New drug | 2025/09/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2500898 | New drug | 2025/08/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2500897 | New drug | 2025/08/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2500896 | New drug | 2025/08/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2500221 | Supplement | 2025/08/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2500196 | New drug | 2025/02/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2500195 | New drug | 2025/02/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
JK06注射液 · No verified English name 1 records · Latest accepted 2026/10/22
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXSL2601163 | New drug | 2026/10/22 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0150片 · No verified English name 15 records · Latest accepted 2026/10/10
Supplement · 3New drug · 12
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXSB2600295 | Supplement | 2026/10/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSB2600294 | Supplement | 2026/10/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSB2600293 | Supplement | 2026/10/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600032 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600031 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600030 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600029 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600028 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600027 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600026 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600025 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600023 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600022 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600021 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXSL2600020 | New drug | 2026/01/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0120CSA片 · No verified English name 6 records · Latest accepted 2026/09/29
New drug · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2601215 | New drug | 2026/09/29 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2601214 | New drug | 2026/09/29 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2600724 | New drug | 2026/06/16 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2600723 | New drug | 2026/06/16 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2600722 | New drug | 2026/06/16 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2600721 | New drug | 2026/06/16 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0132注射液 · No verified English name 2 records · Latest accepted 2026/08/12
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2600293 | Supplement | 2026/08/12 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Hybio Pharmaceutical Co.,Ltd. | CDE ↗ |
| CXHB2600292 | Supplement | 2026/08/12 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Hybio Pharmaceutical Co.,Ltd. | CDE ↗ |
沙库巴曲阿利沙坦氨氯地平片 · No verified English name 2 records · Latest accepted 2026/07/21
New drug · 2
GW906注射液 · No verified English name 1 records · Latest accepted 2026/07/15
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2600222 | Supplement | 2026/07/15 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Chengdu Tian Tai Shan Pharmaceutical Co., Ltd. romanized | CDE ↗ |
沙库巴曲阿利沙坦钙片 · No verified English name 4 records · Latest accepted 2026/07/01
Supplement · 2New drug · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601244 | Supplement | 2026/07/01 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2601243 | Supplement | 2026/07/01 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHS2300060 | New drug | 2023/07/07 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHS2300059 | New drug | 2023/07/07 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Sacubitril Valsartan Sodium Tablets 2 records · Latest accepted 2026/06/11
Supplement · 2
SAL0195注射液 · No verified English name 1 records · Latest accepted 2026/05/20
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2600605 | New drug | 2026/05/20 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Shenzhen Shi Ge Bi Jia Fen Zi Drug Innovation Center Co., Ltd. romanized | CDE ↗ |
Cefazolin Sodium for Injection 2 records · Latest accepted 2026/05/14
Supplement · 2
Ceftriaxone Sodium for Injection 1 records · Latest accepted 2026/05/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2650117 | Supplement | 2026/05/14 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0167片 · No verified English name 3 records · Latest accepted 2026/04/30
New drug · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2600519 | New drug | 2026/04/30 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2600518 | New drug | 2026/04/30 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2600517 | New drug | 2026/04/30 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0139片 · No verified English name 3 records · Latest accepted 2026/04/29
Supplement · 1New drug · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2600119 | Supplement | 2026/04/29 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2500943 | New drug | 2025/09/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2500942 | New drug | 2025/09/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0120片 · No verified English name 12 records · Latest accepted 2026/03/24
Supplement · 6New drug · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2600082 | Supplement | 2026/03/24 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2600081 | Supplement | 2026/03/24 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2500179 | Supplement | 2025/07/05 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2500178 | Supplement | 2025/07/05 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2500177 | Supplement | 2025/07/05 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2500176 | Supplement | 2025/07/05 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400513 | New drug | 2024/05/21 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400512 | New drug | 2024/05/21 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2300774 | New drug | 2023/07/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2300773 | New drug | 2023/07/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2300141 | New drug | 2023/01/31 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2300140 | New drug | 2023/01/31 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
苯甲酸福格列汀片 · No verified English name 4 records · Latest accepted 2026/02/25
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2600388 | Supplement | 2026/02/25 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2600387 | Supplement | 2026/02/25 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2500414 | Supplement | 2025/03/01 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2500413 | Supplement | 2025/03/01 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
阿利沙坦酯片 · No verified English name 2 records · Latest accepted 2026/02/11
Supplement · 2
SAL0145注射液 · No verified English name 1 records · Latest accepted 2026/01/07
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2600021 | New drug | 2026/01/07 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0137片 · No verified English name 3 records · Latest accepted 2025/10/15
New drug · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2501110 | New drug | 2025/10/15 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2501109 | New drug | 2025/10/15 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2501108 | New drug | 2025/10/15 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Fluvastatin Sodium Extended Release Tablets 1 records · Latest accepted 2025/09/28
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2503534 | Generic | 2025/09/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
泰卡西单抗注射液 · No verified English name 2 records · Latest accepted 2025/09/19
New drug · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXSS2500097 | New drug | 2025/09/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized | CDE ↗ |
| CXSS2500096 | New drug | 2025/09/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized | CDE ↗ |
Clopidogrel Hydrogen Sulphate Tablets 4 records · Latest accepted 2025/07/24
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2501482 | Supplement | 2025/07/24 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2400834 | Supplement | 2024/06/18 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2201085 | Supplement | 2022/07/04 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2201084 | Supplement | 2022/07/04 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
阿利沙坦酯氨氯地平片 · No verified English name 2 records · Latest accepted 2025/07/08
Supplement · 1New drug · 1
SAL0112片 · No verified English name 9 records · Latest accepted 2025/03/18
Supplement · 3New drug · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2500065 | Supplement | 2025/03/18 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2500064 | Supplement | 2025/03/18 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2500063 | Supplement | 2025/03/18 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200368 | New drug | 2022/06/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200367 | New drug | 2022/06/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200366 | New drug | 2022/06/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200344 | New drug | 2022/05/31 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200343 | New drug | 2022/05/31 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200342 | New drug | 2022/05/31 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Ceftazidime for Injection 5 records · Latest accepted 2025/01/15
Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550048 | Supplement | 2025/01/15 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2550047 | Supplement | 2025/01/15 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2450598 | Supplement | 2024/12/06 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2450597 | Supplement | 2024/12/06 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHB2350514 | Supplement | 2023/07/01 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
恩那度司他片 · No verified English name 20 records · Latest accepted 2024/12/17
New drug · 8Generic · 12
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2401389 | New drug | 2024/12/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2401388 | New drug | 2024/12/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2402262 | Generic | 2024/07/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2402261 | Generic | 2024/07/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2402260 | Generic | 2024/07/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2402145 | Generic | 2024/07/12 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2402144 | Generic | 2024/07/12 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2402143 | Generic | 2024/07/12 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400505 | New drug | 2024/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400504 | New drug | 2024/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400503 | New drug | 2024/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400502 | New drug | 2024/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400501 | New drug | 2024/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2400500 | New drug | 2024/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHL2300102 | Generic | 2023/08/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHL2300101 | Generic | 2023/08/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHL2300100 | Generic | 2023/08/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHL2300062 | Generic | 2023/04/22 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHL2300061 | Generic | 2023/04/22 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHL2300060 | Generic | 2023/04/22 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0114片 · No verified English name 11 records · Latest accepted 2024/12/06
Supplement · 5New drug · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2400277 | Supplement | 2024/12/06 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2400276 | Supplement | 2024/12/06 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2400188 | Supplement | 2024/09/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2400187 | Supplement | 2024/09/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2400186 | Supplement | 2024/09/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2101724 | New drug | 2021/12/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2101723 | New drug | 2021/12/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2101722 | New drug | 2021/12/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2101721 | New drug | 2021/12/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2101720 | New drug | 2021/12/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2101719 | New drug | 2021/12/08 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Olmesartan Medoxomil Tablets 1 records · Latest accepted 2024/04/09
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2400478 | Supplement | 2024/04/09 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
阿利沙坦酯吲达帕胺缓释片 · No verified English name 3 records · Latest accepted 2023/09/12
New drug · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHS2300079 | New drug | 2023/09/12 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2101031 | New drug | 2021/04/15 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2100011 | New drug | 2021/01/09 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
S086片 · No verified English name 1 records · Latest accepted 2023/02/24
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2300248 | New drug | 2023/02/24 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
苯甲酸复格列汀片 · No verified English name 4 records · Latest accepted 2023/02/10
New drug · 2Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHS2300029 | New drug | 2023/02/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHS2300028 | New drug | 2023/02/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2100023 | Supplement | 2021/02/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2100022 | Supplement | 2021/02/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Cefuroxime Sodium for Injection 1 records · Latest accepted 2023/02/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2350136 | Supplement | 2023/02/03 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
SAL0119片 · No verified English name 6 records · Latest accepted 2022/11/19
New drug · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2200915 | New drug | 2022/11/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200914 | New drug | 2022/11/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200913 | New drug | 2022/11/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200912 | New drug | 2022/11/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200911 | New drug | 2022/11/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2200910 | New drug | 2022/11/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Cefotaxime Sodium For Injection 2 records · Latest accepted 2022/06/23
Supplement · 2
SAL0104胶囊 · No verified English name 10 records · Latest accepted 2022/06/14
Supplement · 6New drug · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2200082 | Supplement | 2022/06/14 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2200081 | Supplement | 2022/06/14 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2101029 | Supplement | 2021/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2101028 | Supplement | 2021/05/17 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2101027 | Supplement | 2021/05/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHB2101026 | Supplement | 2021/05/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2100022 | New drug | 2021/01/16 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2100023 | New drug | 2021/01/14 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2100021 | New drug | 2021/01/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CXHL2100020 | New drug | 2021/01/13 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Enarodustat Tablets 3 records · Latest accepted 2022/01/04
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2102356 | Generic | 2022/01/04 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2102355 | Generic | 2022/01/04 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| CYHS2102354 | Generic | 2022/01/04 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
Changes in the last 90 days
14 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Accepted: 12 applicationsNo longer listed under review: 2 applications
- 2026/11/10Accepted
SAL0140片 · No verified English name
CXHB2600490
Fact date: 2026/11/10 · Date added to this site: 2026/11/11
View source ↗ - 2026/11/10Accepted
SAL0140片 · No verified English name
CXHB2600489
Fact date: 2026/11/10 · Date added to this site: 2026/11/11
View source ↗ - 2026/11/10Accepted
SAL0140片 · No verified English name
CXHB2600488
Fact date: 2026/11/10 · Date added to this site: 2026/11/11
View source ↗ - 2026/11/10Accepted
SAL0140片 · No verified English name
CXHB2600487
Fact date: 2026/11/10 · Date added to this site: 2026/11/11
View source ↗ - 2026/11/10Accepted
SAL0140片 · No verified English name
CXHB2600486
Fact date: 2026/11/10 · Date added to this site: 2026/11/11
View source ↗ - 2026/11/10Accepted
SAL0140片 · No verified English name
CXHB2600485
Fact date: 2026/11/10 · Date added to this site: 2026/11/11
View source ↗ - 2026/10/24No longer listed under review
SAL0132注射液 · No verified English name
CXHB2600293
Fact date: 2026/10/24 · Date added to this site: 2026/10/24
Accepted: 2026/08/12
no longer on the CDE under-review list as of the data cut-off; the review / approval outcome is to be checked
View source ↗ - 2026/10/24No longer listed under review
SAL0132注射液 · No verified English name
CXHB2600292
Fact date: 2026/10/24 · Date added to this site: 2026/10/24
Accepted: 2026/08/12
no longer on the CDE under-review list as of the data cut-off; the review / approval outcome is to be checked
View source ↗ - 2026/10/22Accepted
JK06注射液 · No verified English name
CXSL2601163
Fact date: 2026/10/22 · Date added to this site: 2026/10/23
View source ↗ - 2026/10/10Accepted
SAL0150片 · No verified English name
CXSB2600295
Fact date: 2026/10/10 · Date added to this site: 2026/10/22
View source ↗ - 2026/10/10Accepted
SAL0150片 · No verified English name
CXSB2600294
Fact date: 2026/10/10 · Date added to this site: 2026/10/22
View source ↗ - 2026/10/10Accepted
SAL0150片 · No verified English name
CXSB2600293
Fact date: 2026/10/10 · Date added to this site: 2026/10/22
View source ↗ - 2026/09/29Accepted
SAL0120CSA片 · No verified English name
CXHL2601215
Fact date: 2026/09/29 · Date added to this site: 2026/10/22
View source ↗ - 2026/09/29Accepted
SAL0120CSA片 · No verified English name
CXHL2601214
Fact date: 2026/09/29 · Date added to this site: 2026/10/22
View source ↗
Under review
22 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| SAL0140片 · No verified English name | CXHB2600490 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0140片 · No verified English name | CXHB2600489 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0140片 · No verified English name | CXHB2600488 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0140片 · No verified English name | CXHB2600487 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0140片 · No verified English name | CXHB2600486 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0140片 · No verified English name | CXHB2600485 | Supplement | 2026/11/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| JK06注射液 · No verified English name | CXSL2601163 | New drug | 2026/10/22 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0150片 · No verified English name | CXSB2600295 | Supplement | 2026/10/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0150片 · No verified English name | CXSB2600294 | Supplement | 2026/10/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0150片 · No verified English name | CXSB2600293 | Supplement | 2026/10/10 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0120CSA片 · No verified English name | CXHL2601215 | New drug | 2026/09/29 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL0120CSA片 · No verified English name | CXHL2601214 | New drug | 2026/09/29 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 沙库巴曲阿利沙坦氨氯地平片 · No verified English name | CXHS2600105 | New drug | 2026/07/21 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 沙库巴曲阿利沙坦钙片 · No verified English name | CYHB2601244 | Supplement | 2026/07/01 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 沙库巴曲阿利沙坦钙片 · No verified English name | CYHB2601243 | Supplement | 2026/07/01 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Cefazolin Sodium for Injection | CYHB2650119 | Supplement | 2026/05/14 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Cefazolin Sodium for Injection | CYHB2650118 | Supplement | 2026/05/14 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Ceftriaxone Sodium for Injection | CYHB2650117 | Supplement | 2026/05/14 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | CYHB2502609 | Supplement | 2025/12/30 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Fluvastatin Sodium Extended Release Tablets | CYHS2503534 | Generic | 2025/09/28 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 泰卡西单抗注射液 · No verified English name | CXSS2500097 | New drug | 2025/09/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized | CDE ↗ |
| 泰卡西单抗注射液 · No verified English name | CXSS2500096 | New drug | 2025/09/19 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
43 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Ceftazidime for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20033564 | 2026/02/06 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Ceftazidime for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20033565 | 2026/02/06 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Ceftazidime for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20033563 | 2024/08/01 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefotaxime Sodium For Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H44021403 | 2023/10/27 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefuroxime Sodium for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20030540 | 2023/10/15 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20234256 | 2023/10/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 恩那度司他片 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20233662 | 2023/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 恩那度司他片 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20233664 | 2023/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 恩那度司他片 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20233663 | 2023/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Cefotaxime Sodium For Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H44023217 | 2023/01/06 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefodizime Sodium for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20113394 | 2022/07/29 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Levetiracetam Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20217076 | — | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefoxitin Sodium for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20057503 | 2021/12/22 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefoxitin Sodium for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20057504 | 2021/12/22 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 注射用盐酸头孢吡肟 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20041632 | 2021/11/01 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 注射用盐酸头孢吡肟 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20041631 | 2021/11/01 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Sitafloxacin Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20213601 | 2021/07/20 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Erlotinib Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20213570 | 2021/07/06 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Erlotinib Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20213571 | 2021/07/06 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Cefuroxime Sodium for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20000410 | 2021/06/15 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefuroxime Sodium for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20020182 | 2021/06/15 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Imatinib Mesylate Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20213416 | 2021/05/26 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Imatinib Mesylate Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20213417 | 2021/05/26 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Bivalirudin for Injection | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20110095 | 2021/04/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Rivaroxaban Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20213211 | 2021/03/23 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20213047 | 2021/01/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20203552 | 2020/11/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20203553 | 2020/11/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20203423 | 2020/08/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20203422 | 2020/08/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Lercanidipine Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20203270 | 2020/06/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Clopidogrel Hydrogen Sulphate Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20120018 | 2020/05/14 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Moxifloxacin Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20203062 | 2020/02/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levetiracetam Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20143163 | 2019/10/28 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Olmesartan Medoxomil Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20193216 | 2019/07/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Benazepril Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20043648 | 2019/04/15 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Benazepril Hydrochloride Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20054771 | 2019/04/15 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Pitavastatin Calcium Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20193061 | 2019/03/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Desloratadine Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20020092 | 2019/02/26 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Levetiracetam extended-release tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20193059 | 2019/02/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ticagrelor Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20184165 | 2018/11/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ticagrelor Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20183320 | 2018/07/31 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Clopidogrel Hydrogen Sulphate Tablets | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 国药准字H20120035 | 2017/12/27 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
18 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 西他沙星 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20200001541 | A | 2026/04/02 | CDE ↗ |
| 氟伐他汀钠 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190009733 | A | 2025/01/27 | CDE ↗ |
| 氯雷他定 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190007851 | A | 2024/09/12 | CDE ↗ |
| 头孢西丁钠 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190007848 | A | 2025/06/28 | CDE ↗ |
| 左乙拉西坦 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190007418 | A | 2023/10/11 | CDE ↗ |
| 头孢地嗪钠 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190006151 | A | 2025/03/13 | CDE ↗ |
| 比伐芦定 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190005997 | A | — | CDE ↗ |
| 头孢尼西钠 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190004280 | A | 2024/09/12 | CDE ↗ |
| 头孢米诺钠 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190004277 | A | 2024/09/14 | CDE ↗ |
| 盐酸头孢吡肟/L-精氨酸 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190004117 | A | 2024/09/12 | CDE ↗ |
| 帕米膦酸二钠 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190004108 | A | 2024/09/12 | CDE ↗ |
| 盐酸头孢吡肟 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190002920 | A | 2024/06/06 | CDE ↗ |
| 头孢呋辛钠 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20190002261 | A | 2025/04/26 | CDE ↗ |
| 盐酸厄洛替尼 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20180001455 | A | 2026/03/31 | CDE ↗ |
| 西他沙星 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20180000984 | I | — | CDE ↗ |
| 奥美沙坦酯 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20170001218 | A | 2024/06/06 | CDE ↗ |
| 匹伐他汀钙 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20170001144 | A | 2024/05/08 | CDE ↗ |
| 盐酸莫西沙星 · No verified English name | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Y20170000820 | A | 2023/09/14 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
48 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| 注射用SAL012 · No verified English name | CXSL2600858 | New drug | 2026/08/13 | Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 苯磺酸左氨氯地平片 · No verified English name | CYHB2600832 | Supplement | 2026/04/28 | Shanxi Hua Xia Tai Kang Pharmaceuticals Group Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 苯磺酸左氨氯地平片 · No verified English name | CYHB2600831 | Supplement | 2026/04/28 | Shanxi Hua Xia Tai Kang Pharmaceuticals Group Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Trazodone Hydrochloride Tablets | CYHB2600745 | Supplement | 2026/04/14 | Fujian Dong Rui Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Trazodone Hydrochloride Tablets | CYHB2600744 | Supplement | 2026/04/14 | Fujian Dong Rui Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Compound Glycyrrhizin Tablets | CYHS2504416 | Generic | 2025/12/26 | Guangdong Yue He Ze Drug Research Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Benazepril Hydrochloride and Hydrochlorothiazide Tablets | CYHS2503864 | Generic | 2025/11/05 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Safinamide Methansulfonate Tablets | CYHS2503380 | Generic | 2025/09/12 | Shandong Lukang Pharmaceutical Co.,Ltd.; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Safinamide Methansulfonate Tablets | CYHS2503379 | Generic | 2025/09/12 | Shandong Lukang Pharmaceutical Co.,Ltd.; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 瑞舒伐他汀钙口崩片 · No verified English name | CYHS2502966 | Generic | 2025/08/14 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 瑞舒伐他汀钙口崩片 · No verified English name | CYHS2502965 | Generic | 2025/08/14 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 辅酶Q??片 · No verified English name | CYHS2502770 | Generic | 2025/08/01 | Xizang Ao Si Bi Xiu Pharmaceuticals Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL023注射液 · No verified English name | CXSL2500445 | New drug | 2025/06/04 | Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Fluvoxamine Maleate Tablets | CYHB2500933 | Supplement | 2025/05/09 | Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| YOLT-101注射液 · No verified English name | CXSL2500313 | New drug | 2025/04/17 | Yao Tang (Nanjing) Bio Technology Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Perospirone Hydrochloride Tablets | CYHS2500119 | Generic | 2025/01/08 | Shenzhen Shi Fan Gu Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Perospirone Hydrochloride Tablets | CYHS2500118 | Generic | 2025/01/08 | Shenzhen Shi Fan Gu Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Benazepril Hydrochloride and Hydrochlorothiazide Tablets | CYHS2404056 | Generic | 2024/11/26 | Guangdong Wan Tai Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 苯磺酸左氨氯地平片 · No verified English name | CYHS2404052 | Generic | 2024/11/26 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 苯磺酸左氨氯地平片 · No verified English name | CYHS2404051 | Generic | 2024/11/26 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 匹伐他汀钙口崩片 · No verified English name | CYHS2403538 | Generic | 2024/10/18 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 匹伐他汀钙口崩片 · No verified English name | CYHS2403537 | Generic | 2024/10/18 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 匹伐他汀钙口崩片 · No verified English name | CYHS2403536 | Generic | 2024/10/18 | Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Trazodone Hydrochloride Tablets | CYHS2402998 | Generic | 2024/09/11 | Zhong Run Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Trazodone Hydrochloride Tablets | CYHS2402997 | Generic | 2024/09/11 | Zhong Run Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 重组全人源抗PCSK9单克隆抗体注射液 · No verified English name | CXSL2400547 | New drug | 2024/08/17 | Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL023注射液 · No verified English name | CXSL2400444 | New drug | 2024/07/12 | Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 苯磺酸氨氯地平口崩片 · No verified English name | CYHS2401715 | Generic | 2024/06/07 | Guangdong Wan Tai Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 苯磺酸氨氯地平口崩片 · No verified English name | CYHS2400205 | Generic | 2024/01/13 | Guangdong Wan Tai Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 苯磺酸氨氯地平口崩片 · No verified English name | CYHS2400204 | Generic | 2024/01/13 | Guangdong Wan Tai Ke Chuang Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 利伐沙班口崩片 · No verified English name | CYHS2400093 | Generic | 2024/01/09 | Guangdong Yue He Ze Drug Research Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 利伐沙班口崩片 · No verified English name | CYHS2400092 | Generic | 2024/01/09 | Guangdong Yue He Ze Drug Research Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Ceftazidime for Injection | CYHB2350869 | Supplement | 2023/11/22 | Guo Yao Group Zhi Jun (Shenzhen) Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Agomelatine Tablets | CYHS2302531 | Generic | 2023/09/20 | Shenzhen Shi Fan Gu Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 重组全人源抗PCSK9单克隆抗体注射液 · No verified English name | CXSB2300075 | Supplement | 2023/07/19 | Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL023注射液 · No verified English name | CXSL2300332 | New drug | 2023/05/12 | Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Fluvoxamine Maleate Tablets | CYHS2300093 | Generic | 2023/01/11 | Shenzhen Shi Fan Gu Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| SAL008注射液 · No verified English name | CXSL2200503 | New drug | 2022/10/09 | Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | CYHB2200770 | Supplement | 2022/05/24 | Topfond Pharmaceutical Co., Ltd.; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | CYHB2200771 | Supplement | 2022/05/11 | Topfond Pharmaceutical Co., Ltd.; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| 重组人神经调节蛋白-1-抗HER3抗体融合蛋白注射液 · No verified English name | CXSL2200177 | New drug | 2022/04/22 | Xin Li Tai (Chengdu) Bio Technology Co., Ltd. romanized; Xin Li Tai (Suzhou) Pharma Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Cefuroxime Sodium for Injection | CYHB2250131 | Supplement | 2022/02/21 | Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Cefuroxime Sodium for Injection | CYHB2250130 | Supplement | 2022/02/21 | Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Cefuroxime Sodium for Injection | CYHB2250129 | Supplement | 2022/02/21 | Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Clopidogrel Hydrogen Sulphate Tablets | CYHB2102181 | Supplement | 2021/11/23 | Zhejiang Jun De Bio Technology Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Clopidogrel Hydrogen Sulphate Tablets | CYHB2102180 | Supplement | 2021/11/23 | Zhejiang Jun De Bio Technology Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Imatinib Mesylate Tablets | CYHB2101947 | Supplement | 2021/10/09 | Guo Yao Yi Xin Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
| Imatinib Mesylate Tablets | CYHB2101946 | Supplement | 2021/10/09 | Guo Yao Yi Xin Pharmaceutical Co., Ltd. romanized; SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/18 · Current coverage may be incomplete
- Chemical-drug catalogue
- Last successful update: 2026/11/18
- API registrations
- Last successful update: 2026/11/18
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.